LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Kivitz, A. [1 ]
Wells, A. F. [2 ]
Vargas, J. Ignacio [3 ]
Baraf, H. S. B. [4 ,5 ]
Rischmueller, M. [6 ,7 ,8 ]
Klaff, J. [9 ]
Khan, N. [9 ]
Li, Y. [9 ]
Carter, K. [9 ]
Friedman, A. [9 ]
Durez, P. [10 ]
机构：
[1] Altoona Ctr Clin Res, Altoona Arthrit Osteoporosis Ctr, Duncansville, PA USA
[2] Aurora Rheumatol & Immunotherapy Ctr, Dept Rheumatol, Franklin, WI USA
[3] Quantum Res, Med, Las Lagos, Chile
[4] Ctr Rheumatol & Bone Res, Rheumatol, Wheaton, MD USA
[5] George Washington Univ, Rheumatol, Washington, DC USA
[6] Queen Elizabeth Hosp, Dept Rheumatol, Woodville, SA, Australia
[7] Basil Hetzel Inst, Rheumatol Res Grp, Woodville, SA, Australia
[8] Univ Adelaide, Adelaide Med Sch, Rheumatol, Adelaide, SA, Australia
[9] AbbVie Inc, Immunol, N Chicago, IL USA
[10] UCLouvain St Luc, Inst Rech Experimentale & Clin Univ St Luc, Brussels, Belgium
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0685
引用
收藏
页码：620 / 621
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Peter Nash
    Laura C. Coates
    Alan J. Kivitz
    Philip J. Mease
    Dafna D. Gladman
    José A. Covarrubias-Cobos
    Oliver FitzGerald
    Dona Fleishaker
    Cunshan Wang
    Joseph Wu
    Ming-Ann Hsu
    Sujatha Menon
    Lara Fallon
    Ana Belén Romero
    Keith S. Kanik
    Rheumatology and Therapy, 2020, 7 : 553 - 580
  • [22] Efficacy and safety of OM-8980 in patients with rheumatoid arthritis: An open-label, long-term, multicenter study
    Bandilla, K
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1999, 60 (12): : 638 - 649
  • [23] Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long- Term Extension Study in Patients with Rheumatoid Arthritis
    Magloire, Annaise
    Keystone, Edward
    Taylor, Peter
    Genovese, Mark
    Schlichting, Douglas
    de la Torre, Inmaculada
    Beattie, Scott
    Rooney, Terence
    SWISS MEDICAL WEEKLY, 2015, 145 : 4S - 5S
  • [24] LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: FINAL RESULTS FROM THE PHASE 2 OPEN-LABEL EXTENSION STUDY
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip J.
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2020, 158 (06) : S1198 - S1198
  • [25] Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study
    Ferrante, M.
    Feagan, B. G.
    Panes, J.
    Baert, F.
    Louis, E.
    Dewit, O.
    Kaser, A.
    Duan, W. R.
    Gustafson, D.
    Liao, X.
    Wallace, K.
    Kalabic, J.
    D'Haens, G. R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S024 - S025
  • [26] Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study
    Taylor, P.
    Genovese, M.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    Lundmark, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 59 - 59
  • [27] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, P.
    Genovese, M. C.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 66
  • [28] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, Peter
    Genovese, Mark
    Keystone, Ed
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : A31 - A31
  • [29] Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study
    Strand, Vibeke
    Tundia, Namita
    Friedman, Alan
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [30] Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
    Genovese, Mark C.
    Kremer, Joel
    Zhong, Sheng
    Friedman, Alan
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345